GAP / ILD-GAP stage I (n = 39/76.5%) | GAP/ILD-GAP stage II (n = 12/23.5%) | P-value | |
---|---|---|---|
Age (y) | 63.4 ± 11.6 | 71.5 ± 5.5 | 0.024 |
Age at death (y) | 72.6 ± 9.9 | 76.6 ± 5.6 | 0.266 |
Male sex | 16 (41.0) | 12 (100.0) | <0.001 |
UIP pattern | 25 (64.1) | 6 (50.0) | 0.502 |
Smoking* | |||
Never | 19 (48.7) | 1 (9.1) | 0.033a |
Ex-smoker | 15 (38.5) | 7 (63.6) | |
Current smoker | 5 (12.8) | 3 (27.3) | |
Serology | |||
Positive RF** | 29 (78.4) | 11 (91.7) | 0.420a |
Positive ANA*** | 4 (14.3) | 2 (22.2) | 0.620a |
Medications | |||
Steroids | 36 (92.3) | 10 (83.3) | 0.580a |
MTX | 25 (64.1) | 4 (33.3) | 0.060 |
Biological drugs | 11 (28.2) | 1 (8.3) | 0.250a |
Lung functions | |||
FVC % pred | 89.8 ± 15.8 | 72.6 ± 8.5 | <0.001 |
FEV1 % pred | 85.1 ± 16.3 | 72.3 ± 8.9 | 0.013 |
DLCO % pred | 76.8 ± 15.6 | 52.8 ± 12.7 | <0.001 |
RA duration (y) | 15.7 ± 10.6 | 14.8 ± 14.4 | 0.808 |
CPI points | 22.4 ± 12.2 | 42.8 ± 9.3 | <0.001 |